Abbott Laboratories’ (ABT) drug-discovery arm is focusing on fewer diseases, but it has more promising drug candidates than in recent years partly because of acquisitions and license deals, a top executive said. “We’ve had a very aggressive in-licensing effort,” John Leonard, senior vice president of pharmaceuticals research and development”...
